Skip to main content
. 2023 Mar 22;130(9):1558–1572. doi: 10.1017/S0007114523000739

Table 5.

Modified Poisson regression analyses (risk ratios) for associations between maternal delivery and venous cord Se biomarkers and adverse birth outcomes

(95 % confidence intervals)

Outcome Se biomarker* Timepoint n Unadjusted risk ratio 95 % CI P n Adjusted risk ratio 95 % CI P
Small-for-gestational age WBSe Delivery 445 1·03 0·96, 1·1 0·4 416 1·04 0·96, 1·1 0·3
WBSe Venous cord 441 1·06 0·99, 1·1 0·07 411 1·07 1·0, 1·1 0·05
Serum Se Delivery 496 1·02 0·9, 1·1 0·7 486 1·05 0·9, 1·2 0·4
SEPP1 Delivery 650 0·99 0·85, 1·2 0·9 643 1·03 0·9, 1·2 0·7
SEPP1 Venous cord 555 0·8 0·6, 1·0 0·08 527 0·7 0·5, 0·9 0·01
Low birth weight WBSe Delivery 445 1·05 0·95, 1·2 0·3 416 1·12 1·0, 1·3 0·04
WBSe Venous cord 441 1·11 1·0, 1·2 0·02 411 1·08 0·99, 1·2 0·1
Serum Se Delivery 496 1·06 0·93, 1·2 0·4 486 1·12 0·97, 1·3 0·1
SEPP1 Delivery 650 0·99 0·85, 1·2 0·9 643 1·2 1·0, 1·5 0·1
SEPP1 Venous cord 555 0·8 0·6, 1·0 0·08 527 0·9 0·6, 1·3 0·5
Preterm birth WBSe Delivery 467 1·01 0·8, 1·2 0·9 418 1·31 0·9, 1·9 0·2
WBSe Venous cord 448 1·13 0·96, 1·3 0·2 413 1·01 0·8, 1·3 0·9
Serum Se Delivery 517 1·11 0·9, 1·4 0·3 487 0·99 0·7, 1·4 0·9
SEPP1 Delivery 677 0·95 0·7, 1·3 0·8 644 1·06 0·67, 1·7 0·8
SEPP1 Venous cord 562 0·5 0·26, 1·0 0·06 529 1·2 0·5, 3·0 0·7

WBSe, whole blood selenium; SEPP1, selenoprotein P.

*

WBSe scaled to represent the change in anthropometric outcome for every 10 µg/l increase in WBSe. Serum Se scaled to represent the change in anthropometric outcome for every 10 µg/l increase in serum Se. SEPP1 scaled to represent the change in anthropometric outcome for every 1000 µg/l increase in SEPP1.

Models adjusted for infant sex, season of birth, maternal age, maternal education, maternal height, maternal BMI, gravidity, vitamin D treatment group, delivery CRP, asset index quintiles, daily protein intake (kg), smoking and tobacco use during pregnancy.